Αρχική World News Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood... World News Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma Από Ogkologos - 11 Νοεμβρίου, 2025 417 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... 5 Ιουλίου, 2018 Neoadjuvant Serplulimab with S-1 Plus Oxaliplatin Followed by Adjuvant Serplulimab Significantly... 30 Ιουνίου, 2026 FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection 14 Ιανουαρίου, 2026 Health inequalities: “We have a moral duty to reduce them” 15 Φεβρουαρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... Adding Olanzapine to Standard Triple Antiemetic Therapy for the Prevention of... Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated...